dc.contributor.author | Durmaz, Erdem | |
dc.contributor.author | Ozmert, Elif N. | |
dc.contributor.author | Erkekoglu, Pinar | |
dc.contributor.author | Giray, Belma | |
dc.contributor.author | Derman, Orhan | |
dc.contributor.author | Hincal, Filiz | |
dc.contributor.author | Yurdakok, Kadriye | |
dc.date.accessioned | 2019-12-10T10:50:06Z | |
dc.date.available | 2019-12-10T10:50:06Z | |
dc.date.issued | 2010 | |
dc.identifier.issn | 0031-4005 | |
dc.identifier.uri | https://doi.org/10.1542/peds.2009-0724 | |
dc.identifier.uri | http://hdl.handle.net/11655/14314 | |
dc.description.abstract | OBJECTIVE: Several untoward health effects of phthalates, which are a group of industrial chemicals with many commercial uses including personal-care products and plastic materials, have been defined. The most commonly used, di-(2-ethylhexyl)-phthalate (DEHP), is known to have antiandrogenic or estrogenic effects or both. Mono-(2-ethylhexyl)-phthalate (MEHP) is the main metabolite of DEHP. In this study, we aimed to determine the plasma DEHP and MEHP levels in pubertal gynecomastia cases. PATIENTS AND METHODS: The study group comprised 40 newly diagnosed pubertal gynecomastia cases who were admitted to Hacettepe University Ihsan Dogramaci Children's Hospital. The control group comprised 21 age-matched children without gynecomastia or other endocrinologic disorder. Plasma DEHP and MEHP levels were measured by using high-performance liquid chromatography. Serum hormone levels were determined in some pubertal gynecomastia cases according to the physician's evaluation. RESULTS: Plasma DEHP and MEHP levels were found to be statistically significantly higher in the pubertal gynecomastia group compared with the control group (P<.001) (DEHP, 4.66 +/- 1.58 and 3.09 +/- 0.90 mu g/mL, respectively [odds ratio: 2.77 (95% confidence interval: 1.48-5.21)]; MEHP, 3.19 +/- 1.41 and 1.37 +/- 0.36 mu g/mL [odds ratio: 24.76 (95% confidence interval: 3.5-172.6)]). There was a statistically significant correlation between plasma DEHP and MEHP levels (r: 0.58; P < .001). In the pubertal gynecomastia group, no correlation could be determined between plasma DEHP and MEHP levels and any of the hormone levels. CONCLUSIONS: DEHP, which has antiandrogenic or estrogenic effects, may be an etiologic factor in pubertal gynecomastia. These results may pioneer larger-scale studies on the etiologic role of DEHP in pubertal gynecomastia. Pediatrics 2010; 125: e122-e129 | |
dc.language.iso | en | |
dc.publisher | Amer Acad Pediatrics | |
dc.relation.isversionof | 10.1542/peds.2009-0724 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Pediatrics | |
dc.title | Plasma Phthalate Levels in Pubertal Gynecomastia | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Pediatrics | |
dc.contributor.department | Çocuk Sağlığı ve Hastalıkları | |
dc.identifier.volume | 125 | |
dc.identifier.issue | 1 | |
dc.identifier.startpage | E122 | |
dc.identifier.endpage | E129 | |
dc.description.index | WoS | |
dc.description.index | Scopus | |